A study of warning letters issued to clinical investigators by the United States Food and Drug Administration

Bramstedt, Katrina A.
June 2004
Clinical & Investigative Medicine;Jun2004, Vol. 27 Issue 3, p129
Academic Journal
Purpose: This study explores the ethical issues contained in warning letters issued to clinical researchers by the Food and Drug Administration (FDA) in the USA. Methods: The online FDA Warning Letter Index was reviewed for letters issued to drug and device researchers in the USA and Canada under the violation subject "Clinical Investigator" for the period February 2002 through February 2004. The resultant letters were evaluated for the presence of 7 research ethics themes: deviation from investigational plan; informed consent; adverse event reporting; study reporting; study super vision; institutional review-board approval; and misconduct. Results: Thirty-six FDA warning letters ad- dressing violations of 58 protocols were issued to researchers during the 25 months studied. Researchers performing pulmonary medicine studies received the most warning letters (12), followed by oncology (10) and cardiology (9) researchers. The most common regulatory violations were deviation from the research plan, a flawed or nonexistent consent process, and failure to report or late reporting of adverse events. Three warning letters (8%) mentioned study misconduct, including data fabrication. Conclusions: Warning letters are informative about good practice, ethics and participant protection in research. As distressing as the content in an FDA warning letter may be to investigators receiving it, that information can become an educational tool for all members of the research team. These letters are also informative as to what the FDA is looking for when they audit clinical trials.


Related Articles

  • FDA inks draft guidance for risk-based trial monitoring.  // Medical Device Daily;8/30/2011, Vol. 15 Issue 165, p1 

    The article focuses on a draft guidance for clinical trial monitoring that has been issued by the U.S. Food and Drug Administration (FDA). Noted is the aim of the agency to promote the increased use of centralized monitoring methods. The FDA comments on a guidance from the International...

  • Global clinical trials: Calling the hype to task. Redfearn, Suz // CenterWatch Monthly;Sep2015, Vol. 22 Issue 9, p1 

    The article focuses on various aspects related to the U.S. Food and Drug Administration (FDA) regulated clinical trials. It highlights the data released by Tufts Center for the Study of Drug Development (Tufts CSDD), which discusses the decrease in number of clinical investigators in China and...

  • …and I'll Take the Low Road. Clinton, Patrick // Pharmaceutical Executive;Jul2004, Vol. 24 Issue 7, p14 

    Focuses on the debate over the creation of a registry of clinical trial results. Perception of some people that a clinical trials registry is a simple matter of good science; Improvement in access to clinical studies; View that the Food and Drugs Administration should be the lone decision-maker...

  • A Declaration of Action. Rucker, David; Parno, Jeff // Applied Clinical Trials;Sep2005, Vol. 14 Issue 9, p62 

    Considers the implications of the U.S. Food and Drug Administration's (FDA) Critical Path Initiative for medical products development for the clinical research industry in the United States. Findings of the March 2004 FDA report "Challenge and Opportunity on the Critical Path to New Medical...

  • Forgotten Voices in the Transparency Debate. Getz, Kenneth A. // Applied Clinical Trials;Apr2006, Vol. 15 Issue 4, p42 

    The article comments on the debate concerning improving transparency in online clinical trials in the U.S. in 2006. At the heart of the debate is the need to decide whether a single central online registry or many different online locations can best serve the Food and Drug Administration's...

  • Pressure Grows for More Inclusive Clinical Trials. Wechsler, Jill // Applied Clinical Trials;Apr/May2014, Vol. 23 Issue 4/5, p10 

    The article discusses the growing pressure for more inclusive clinical trials. The author talks about the call for biomedical studies to fully examine how new drugs and medical products affect a broad spectrum of patient populations. She tackles a report from the U.S. Food and Drug...

  • The New Road of Cardio-Oncology in Clinical Development. Herron, David S. // Applied Clinical Trials;Apr/May2014, Vol. 23 Issue 4/5, p38 

    The article discusses the developments in cardoi-oncology in clinical development. The author provides an overview about the clinical discipline, cardio-oncology, which aims to bridge the gap between cardiology and oncology and promote safer drugs and better outcomes for cancer patients. Also...

  • Three-Pronged Approach to Optimizing Trial Monitoring. Mitchel, Jules T.; Cho, Timothy; Gittleman, Dean A.; Schloss Markowitz, Judith M.; Yong Joong Kim; Joonhyuk Choi; Hamrell, Michael R.; Nora, Sergio Dalla; Carrara, Dario // Applied Clinical Trials;Jun/Jul2014, Vol. 23 Issue 6/7, p37 

    The article discusses the three-pronged approach to optimize trial monitoring. The author talks about the publication of varied practices of monitoring clinical trials by the Clinical Trials Transformation Initiative (CTTI), a public-private partnership formally established in 2008 by the U.S....

  • The Imperative of Overcoming Barriers to the Conduct of Large, Simple Trials. Eapen, Zubin J.; Lauer, Michael S.; Temple, Robert J. // JAMA: Journal of the American Medical Association;4/9/2014, Vol. 311 Issue 14, p1397 

    The authors discuss a working group convened in May 2013 by the public-private partnership Clinical Trials Transformation Initiative to identify barriers to the conduct of large, simple clinical trials. Topics addressed include enlarging the risk-benefit balance of therapies, making trials...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics